CSA Medical Inc

ALung Technologies develops extracorporeal respiratory support devices, including the Hemolung Respiratory Assist System, designed to remove carbon dioxide from blood and support patients with acute respiratory failure. Its products are intended for hospitals and critical-care clinicians treating patients who need respiratory support, including certain patients with severe COPD or who may otherwise require mechanical ventilation.

Noah Medical is a medical technology company that develops robotic-assisted platforms for bronchoscopic procedures. Its Galaxy System is designed to help pulmonologists and other clinicians navigate the lungs and obtain tissue samples for diagnosing suspected lung cancer and other pulmonary conditions.

Lunair Medical, Inc.Medical DevicesUnited States

66% match

Lunair Medical is developing an implantable neurostimulation device and connected digital platform designed to treat moderate-to-severe sleep apnea. The system utilizes closed-loop phrenic nerve stimulation and respiration sensing to maintain an open airway during sleep without the use of masks or wearables.

Caire Health Holdings, Inc.Medical Equipment ManufacturingUnited States

65% match

CAIRE Health Holdings, Inc. manufactures and supplies medical oxygen therapy equipment, including portable and stationary oxygen concentrators, liquid oxygen systems, and onsite gas generators. The company also provides cardiorespiratory diagnostics devices to healthcare providers, patients, and commercial applications.

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.

Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.